齐拉西酮与利培酮治疗精神分裂症对照研究  

A control study of ziprasidone vs. risperidone in the treatment of schizophrenia

作　　者：季日格 吴焱 

机构地区：[1]乌鲁木齐市精神病福利院,新疆·乌鲁木齐830023

出　　处：《临床心身疾病杂志》2016年第5期41-43,64,共4页Journal of Clinical Psychosomatic Diseases

摘　　要：目的探讨齐拉西酮与利培酮治疗精神分裂症患者的疗效和安全性。方法将100例精神分裂症患者按人院单双号分为研究组与对照组，每组50例，研究组口服齐拉西酮治疗，对照组口服利培酮治疗，观察8周。治疗前后采用阳性与阴性症状量表评定临床疗效，临床总体印象量表评定疾病总的变化和严重性，卡尔加里精神分裂症抑郁量表评定抑郁状况，副反应量表评定不良反应。对两组评定结果进行对比分析。结果治疗后两组各量表评分均较治疗前显著下降（P〈0．01），同期两组各量表评分比较差异均无显著性（P〉0．05）；治疗8周末研究组总有效率为94．0％，对照组为80．0％，研究组总有效率显著高于对照组（x^2=4．33，P〈O．05）。治疗后研究组未出现性欲降低、月经改变不良反应，对照组二者发生率显著高于研究组（P〈0．05）；研究组治疗前后血清泌乳素水平无显著变化（P〉0．05），对照组治疗后较治疗前显著升高（P〈0．01），且显著高于研究组（P〈0．01）。两组肝功能异常、失眠发生率比较差异无显著性（P〉0．05）。结论齐拉西酮与利培酮均能快速改善精神分裂症患者的各种精神症状及抑郁状况，安全性高，但齐拉西酮对血清泌乳素、月经、性欲无明显影响，对女性患者的治疗具有一定优势。Objective To explore the efficacy and safety of ziprasidone and risperidone in the treatment of schizophrenia. Methods A total of 100 schizophrenics were assigned to research and control group of 50 ones each according to odd or even numbers of admission, research group took orally ziprasidone and control did risperidone for 8 weeks. Before and after treatment efficacies were assessed with the Positive and Negative Syndrome Scale （PANSS）, total changes and severity of the disease with the Clinical Global Impression （CGI）, depressive conditions with Calgary Depression Scale for Schizophrenia （CDSS）, and ad- verse reactions with the Treatment Emergent Symptom Scale （TESS）. The assessment results of two groups were contrastively analyzed. Results After treatment scores on all scales of both groups lowered more significantly compared with pretreatment （P〈0.01）, there were no significant group differences in scores on all scales in the corresponding time period （P〉0.05） ; at the end of the 8th week total effective rate was respectively 94.0% in research and 80.0 % in control group, the former significantly higher than the latter （x^2 =4.33,P〈0.05）. After treatment such adverse reactions as decreased libido and menstrual changes didn＇t occur in research group, their incidences were significantly higher in control than research group （P〈0.05）. Post-treatment lactotropin levels had no notable change from pre-treatment in research group （P〉0.05）, heightened more significantly in control group （P〈0.01）, and were significantly high- er in control than research group （P〈0.01）. There were no significant group differences in the incidences of dysfunction of liver and insomnia （P〉0.05）. Conclusion Both ziprasidone and risperidone could rap idly improve all kinds of mental symptoms and depressive conditions of schizophrenics, their total efficacies are equivalent, they have higher safety,but ziprasidone has no notable influences on serum lactotropin, menstruation

关 键 词：精神分裂症 齐拉西酮 利培酮 精神症状 认知功能 阳性与阴性症状量表 临床总体印象量表 卡尔加里精神分裂症抑郁量表 

分 类 号：R749.3[医药卫生—神经病学与精神病学]